Trade the DBV Technologies share!
DBV TECHNOLOGIES

Analysis before buying or selling DBV Technologies shares

Trade the DBV Technologies share!
BUY   SELL
78% of retail CFD accounts lose money - eToro.com
 
Chart provided by Tradingview

If you too are interested in the French company DBV Technologies and wish to trade this stock online, this article will undoubtedly be very useful. You will find explanations about this company with details of all its activities, its main competitors and its recent partnerships as well as an analysis of its strengths and weaknesses and some advice on how to carry out a fundamental analysis of its share price.

Elements to consider before selling or buying DBV Technologies shares

Analysis N°1

The results of the clinical trials of the various products and solutions in development will of course be followed closely by investors. In the medium term, we should learn a little more about the trial phases of ViaskinPT against pertussis and the market launch of Viaskin Peanut.

Analysis N°2

We will also keep a close eye on any announcement concerning the establishment of partnerships or strategic alliances with large pharmaceutical groups, which are indeed essential for the financing of its research.

Analysis N°3

The information communicated by DBV Technologies concerning its strategy to become the world leader in the treatment of allergies is also to be followed with interest, in particular with regard to the extension of Viaskin solutions to other allergies or the development of allergies linked to autoimmune diseases, as well as the marketing of some of its products under its own name.

Analysis N°4

As part of your analysis of the growth of this company and therefore of the possibilities of an upward trend in this value, we will keep an eye on obtaining authorisations for the marketing of treatment candidates developed by this biotech. These decisions have a direct and often very important impact on the company's future turnover and therefore on its performance and profitability. The main health authorities in charge of studying the efficacy and non-dangerousness of a treatment before it is put on the market are the FDA or Food and Drug Authority in the United States and its equivalent in Europe with the EMEA or European Agency for the Evaluation of Medicinal Products.

Trade the DBV Technologies share!
78% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

General presentation of DBV Technologies

Before discovering the environment of the French company DBV Technologies in more detail, we would like to remind you of the activities of this company. DBV Technologies is a biotechnology company specialising in the development of solutions for the diagnosis and treatment of certain food allergies such as cow's milk and peanut allergies. It is particularly known for having developed a patch that allows active ingredients to be administered via the skin.

DBV Technologie also specialises in paediatric allergies and is seeking to develop the first effective treatment for this type of problem.

Among the products that DBV Technologies has developed are the Viaskin Peanit patch for treating peanut allergies and the Viaskin Milk patch for treating cow's milk allergies.

The Viaskin Peanut Patch allows peanut allergic individuals to tolerate some exposure to peanuts and reduces the risk of a systemic allergic reaction in the event of accidental exposure. The patch has received Fast Track designation from the US Food and Drug Administration.

But DBV Technologies has also developed a method for determining childhood allergies, the E-patch. This is a simple to use and extremely reliable patch that allows useful information to be collected.

Analysis before buying or selling DBV Technologies shares
Trade the DBV Technologies share!
78% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

The major competitors of DBV Technologies

The biotech sector is currently booming in France and, as a result, several stocks in this sector are in direct competition with DBV Technologies. Here we present some of these competitors:

Nanobiotix

is developing a treatment using nanoparticles in radiotherapy to optimise the absorption of X-rays into cancer cells without the need to further expose surrounding tissue.

Innate Pharma

Develops immuno-oncology solutions by seeking to treat certain cancers by promoting the recognition and elimination of cancer cells by immune cells.

Coral Biome

Attempts to develop an original treatment for cancer based on marine molecules from coral which, in addition to slowing down the development of the disease, pushes the cancer cells to self-destruct.

Adocia

Specialises in the treatment of diabetes and is developing an insulin formulation to treat diabetic foot ulcers as well as an ultra-rapid insulin that it is developing jointly with the American laboratory Eli Lilly.

Abivax

One of the international leaders in therapeutic vaccines and anti-viral drugs to fight various deadly diseases such as AIDS, hepatitis B, Ebola, dengue and chikungunya.

Prixium Vision

Develops bionic vision systems based on advanced technology and a surgical procedure that should restore sight to blind people.

Biophytis

Specialises in the treatment of age-related diseases, particularly those affecting the eyes and muscles.

Sensorion

Develops treatments for diseases and pathologies of the inner ear.

Theraclion

Specialises in the development of focused ultrasound treatment for breast cancer tumours, allowing patients to avoid more invasive surgery.


The major partners of DBV Technologies

Of course, in order to develop its activities and become one of the major players in biotechnology in France and worldwide, DBV Technologies relies on quality partnerships with other companies and industries in this sector. Here we present three concrete examples of these alliances.

Sanofi

In 2013, DBV Technologies entered into a targeted partnership with the Sanofi group for the development of the Viaskin Peanut and Viaskin Milk food allergy patches. Through this agreement, Sanofi undertook to industrialise the production process of Viaskin's active pharmaceutical ingredients during the development phases and to supply them to DBV Technologies at the commercial stage. The DBV Technologies group was thus able to benefit from Sanofi's expertise in the development of biological products and the manufacture of plant extracts and purified therapeutic proteins.

Nestlé

More recently, in 2016, DBV Technologies signed a strategic partnership agreement with another major group, Nestlé. This agreement concerns a research and development programme with the Nestlé Health Science subsidiary aimed at developing and then marketing a patch test to detect allergies to infant milk proteins. Under this partnership, DBV Technologies will be in charge of the development of the pivotal phase III clinical programme after receiving an initial payment of €10 million from Nestlé and will then receive up to €100 million. The development of the patch test is expected to be completed in 2021 and to result in a first submission for regulatory approval. Of course, Nestlé Health Science Group will then have the exclusive right to commercialise the patch on the world market in return for royalties paid to DBV on these sales.

Trade the DBV Technologies share!
78% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro
Positive factors for DBV Technologies shares
The factors in favour of a rise in the DBV Technologies share price:

First of all, the specialisation and experience of this biotechnology company, which has been in existence since 2002 in the field of transcutaneous diagnostics and treatment of food allergies, is a real asset, as this sector has virtually no competition.

Another advantage of this company is that it focuses on a growing market. Today, it is known that 3-5% of Americans suffer from food allergies. The development and validation of an effective treatment or diagnostic solution will lead to very high sales and therefore high profitability in the long term.

Another strength of DBV Technologies is that it has received breakthrough therapy status for Viaskin Peanut and Fast Track status for Viaskin Milk from the US health regulator.

As we have seen above, the low level of competition in the food allergy market is an asset for the DBV Technologies group, and this is especially true for peanut allergies, as the French biotech is currently the only one working on this specific subject.

Another advantage is that DBV Technologies is focused on developing products that are easy to use. The patch format for limiting the risk of allergic reaction to exposure to a food allergen or for the detection of specific allergies is a real plus compared to other solutions on the market and has no side effects.

Finally, the fact that the company is in a good financial position and has strong liquidity.

Negative factors for DBV Technologies shares
The factors in favour of a drop in the DBV Technologies share price:
  • Firstly, we can talk about the lack of profits made by the DBV Technologies group despite its substantial cash flow. The major and important research carried out by the group over the years has indeed generated very significant costs and required major investments. While this expenditure phase is normal for companies in this sector of activity that depend largely on financing from potential partners, DBV Technologies has only been generating revenue since 2018 but previously recorded losses over several half-years with a total of several million euros lost.
  • As we have just said, the fact that DBV Technologies has to call on external funds to finance itself is another of its major weak points. Thus, in order to cope with the heavy burden of financing its research, the company regularly calls on external financing, which tends to increase its debt burden, with no guarantee of obtaining marketing authorisations for its treatments and therefore of making a profit.
  • Among the major weaknesses of this company, we can also take into account the regulatory restrictions of the high health authorities. There are indeed bodies in charge of approving or disapproving drugs and treatments developed by biotechs such as DBV Technologies, and their decisions have a significant impact on their financial results. Indeed, if a drug candidate developed over many months or even years by DBV Technologies does not obtain the necessary marketing authorisations, the money invested in research is lost and this represents a very significant loss of earnings likely to cause the company's share price to fall.
  • Finally, the last disadvantage of DBV Technologies concerns its share price directly. The share is very volatile, which makes it more risky to trade online, with strong, rapid and sometimes unexpected movements.
The information supplied here is only for indicative purposes and should not be used without the completion of a comprehensive and complete fundamental analysis of this asset notably taking into account exterior data, future publications and announcements and all fundamental events and news that could influence the strengths and weaknesses or make them more or less significant. This information does not in any way constitute recommendations relating to the completion of transactions or a solicitation to buy or sell an asset.

Frequently Asked Questions

Where and how are DBV Technologies shares listed?

The DBV Technologies share price is currently listed on the French stock exchange, i.e. on the Euronext Paris stock exchange. It is also important to note that this company is also part of the composition of various stock market indices, including of course the SBF 120, but also other indices such as the CAC Mid 60, the CAC All sgares, the Cac All tradable, the CAC Mid Small, the CAC PME, Enternext, Next 150, Next Biotech and others.

What is the shareholder structure of DBV Technologies?

The shareholders of DBV Technologies are Bpifrance Participations with 9.39% of the shares, Amundi Asset Management with 4.03% of the shares, Sofinnova Partners with 3.31% of the shares, The Vanguard Group with 2.14% of the shares, Norges Bank Investment Management with 1.75% of the shares, Pierre Genri Benhamou with 1.59% of the shares, VHCP Management with 1.54% of the shares, BlackRock Fund Advirors with 0.79% of the shares, and BPI France Investissement with 0.75% of the shares.

What DBV Technologies news to follow in particular?

If you want to trade DBV Technologies shares effectively, you need to be able to understand and track the most influential news as part of your fundamental analysis of the stock. This includes the group's innovations, strategic partnerships, divestitures or acquisitions, as well as contracts for the commercialisation of certain products and external financing obtained by the group.

Trade the DBV Technologies share!

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.